Medisys PLC (MDY) Providing innovative solutions to the rapidly growing point-of-care diagnostic and healthcare worker safety markets. For more than 35 years, companies in the Medisys group have been advancing healthcare through development, manufacture and distribution of revolutionary medical products. The Group's mission is to become a leading worldwide provider of diagnostic systems and medical safety products enabling rapid, cost effective, on-site delivery of healthcare solutions.
For more than three decades, Medisys' primary operating unit, Hypoguard, has been devoted to advancing personal and professional healthcare management. The Company's core focus is diabetes glucose self-monitoring - a rapidly growing market of nearly $5 billion worldwide.
'Medisys-group.com'
'Hypoguard.com'

15/02/2006
Medisys reported a 'considerable improvement' in trading during the first four months of its financial year, and said the business has been cash-flow neutral for the year to date.
The medical products company said competition in its core long-term care blood glucose monitoring business has not intensified. A drop in sales amid intense competition in the market caused a fall in sales and profits last year.
Sales volumes have recovered to previous highs by cutting prices and offering various promotions, Medisys reported this morning.
Margin improvements have been achieved faster than originally anticipated, it added. The company has benefited from cost saving measures implemented in the second half of the last financial year and cost reductions for its proprietary biosensor products.
Meanwhile, it has completed the development and manufacturing scale up of the first of the new systems it has designed for Menarini, the fifth largest worldwide branded marketer of blood glucose monitoring systems.
While the launch date is not yet clear, (Around March 1) Medisys predicted that sales of the products will be one of its key revenue growth drivers in the current financial year.


LATEST ON MDY V'S ROCHE COURT CASE
MDY V'S ROCHE COURT CASE Case IS Dismissed. http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread
My apologies for any one that was on MDY it looks like we have been stitched up like a kipper the sale of Hypoguard blood glucose monitoring business at that price looks like an sp of 3p against the close of 6.4p what can I say no one could have seen this coming a total sell out and that is what I have done.

Staying for the recovery the results were already built in to the sp IMO.

It looks to me that the results were already priced in hence the pick up from todays low of nearly 26% down. What will get this share going is (1) A pick up in sales (2) new contracts (3) a new CEO (4) a win on the Roche case. Anyone of these can happen at any time so if you are in it can only be up from here.


Dow Jones 9/11/2005
Medisys (MDY.LN) -23% at 2.4p after FY results came below expectations due to the slightly slower uptake of the advanced products, says Code Securities' Michael King. The discontinuation of NewTek diabetes product impacted the profit line with a one-off charge, he adds. Will downgrade 2006 sales to take into account of NewTek discontinuation, but keeps hold recommendation. (EXB)

Is this the bottom ? I would imagine that all the bad news must be factored in now !

hope so--I knew this might be a long haul but I hope we might see a small sign of life soon !

mp
The cc should be decided in January we hope in favour of MDY then there will be some movement in the sp.

All good points from another board.


Production Capacity

As announced previously, during the second half of the year the Group took
delivery of the final pieces of the production and packaging equipment acquired
to increase production capacity for the biosensor range of products. The new
production equipment was fully commissioned towards the end of the year and the
Group now has sufficient capacity to support its business with Menarini and
Liberty, and to cover additional expansion of the products in the US and
international markets.

The increased automation afforded by the introduction of this equipment has
resulted in reduced manufacturing costs and the expected reduction in cost of
goods for the Advance Micro-draw product. Much improved margins were seen during
the last few months of the year, and further improvements are anticipated as the
manufacturing process is further automated, and as volumes increase.


Medisys announced earlier in the year that the US District Court (Southern
District of Indiana Indianapolis Division) found one of the two patents in issue
in the infringement litigation to be unenforceable as a result of inequitable
conduct before the US Patent and Trademark Office during the prosecution of the
patent.

Subsequent to this announcement, Hypoguard was informed that the Court had
issued an Order on Claim Construction for Patent infringement on the remaining
patent in issue. This Order sets out how the Court has determined that the terms
used in the patent shall be construed in an infringement trial to determine
whether the product in issue (in this case, Assure 3) actually infringes the
patent. As a result of this Order, Hypoguard filed a motion asking the Court to
dismiss Roche's Complaint on the basis that, by applying the Court's Claim
Construction Order, no reasonable jury could find that the Assure 3 product
infringes the patent. It is anticipated that the Court will hear the motion in
early 2006.

The Directors remain of the opinion that Hypoguard shall be successful in
defending against the remaining claim. To date, all costs associated with
Hypoguard's defence of the claims have been paid by Apex Biotechnology Corp, the
manufacturer of the Assure products, under the terms of an indemnity provided by
Apex to Hypoguard.

CURRENT TRADING AND PROSPECTS

The current financial year is at an early stage, but to date trading has been in
line with expectations. Growth is expected to come primarily from the biosensor
based products, specifically through the alliance with Menarini and from the
introduction of the Assure Pro system into the LTC market. In addition the cost
savings realised in the latter part of 2005 will help to improve the financial
performance of the Group in the current year.

As noted earlier, the automation equipment commissioned in the latter part of
the year for the Advance Micro-draw products will ensure that improved cost of
goods, and subsequently margins, are achieved during the first half of 2006.

thanks Driver--sounds encouraging we will have to be patient and if bold I should continue to add!! I'm boldly waiting with Yoo Dgt and Pcm must make some dosh soon perhaps 2006 is the year--maybe not an island in the carribean but a nice little flat in Majorca would do me! cheers MP

Lattest on the cc on the cc page looking good for MDY.

http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

British Bulls have got this one as buy confirmed, reached rock bottom give it a few months this will be back at 4 -5p good news permitting

Did you see updated news on court case ?

moneyman
Yes its on the cc page.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

moneyman
Sorry moneyman I just had a look and it was you that put it on the cc page I thought it was mp, moneyplus

just added a few today in the hope they've hit bottom!!

mp
We could see a large hike in the sp when the end of the cc becomes official.

A nice 3m buy at the end of trade we havn't seen that for a while.

Maybe MDY Management can now look to the tatters that was their business - maybe to finding some replacement products to replace the needle-business that was so much - and then so little.
The sp stood about 7p last AGM (early 2005, )
It is now about 2p
That's a loss of 66% - grief that says a lot of folk wanted out.
Come-on MDY- - - find new products - ou could improve investor confidence by having a 1-year halt on all share-options and Director incentives -( they don't work )- what's wrong with "pride in one's work?"
I hold MDY.

hangon
Keep hanging on it will come good in the end.

See ADVFN MDY thread is over-run by idiots !

moneyman
I have seen it; the thread is just a drinking hole for them to visit.

20/01/2005 Roche has ask for another two week extension.

http://www.moneyam.com/InvestorsRoom/posts.php?tid=8721#lastread

The consensus of opinion from other b/boards is that MDY have it in the bag, Im sitting on the fence till we get an rns I wouldnt want to ramp but keep an eye on this Monday morning.